The rationale for pentoxifylline usage in schizophrenia is that it competitively inhibits 5′‐nucleotidase and PDE4 and PDE5, resulting in enhanced intracellular cAMP, protein kinase A (PKA) activation, and suppression of interleukins and TNF‐α production, which ultimately reduce inflammation.31, 32. The gene discussed is PDE4A; the disease is schizophrenia.